Company Encyclopedia
View More
name
YUYUE MEDICAL
002223.SZ
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. engages provision of home medical devices, medical clinical products, and related services in China and internationally. It offers respiratory solutions, including PAP therapy, oxygen concentrators, nebulizers, high flow oxygen therapy, and airway clearances; diabetes management solutions; medical diagnostic devices, such as blood pressure monitors, oximeters, and thermometers; wheelchairs; AEDs; and traditional Chinese medicine product solutions. The company was formerly known as Yuwell medical.
890.25 B
002223.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking2/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE13.36%B
    • Profit Margin21.53%A
    • Gross Margin50.81%B
  • Growth ScoreB
    • Revenue YoY10.17%B
    • Net Profit YoY0.19%C
    • Total Assets YoY7.59%B
    • Net Assets YoY7.66%B
  • Cash ScoreC
    • Cash Flow Margin464.49%C
    • OCF YoY10.17%B
  • Operating ScoreC
    • Turnover0.5C
  • Debt ScoreA
    • Gearing Ratio18.21%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    YUYUE MEDICAL: Overseas revenue maintained rapid growth in the first three quarters

    YUYUE MEDICAL stated in an institutional research report that overseas revenue continued to grow rapidly in the first three quarters, especially in the Southeast Asian and European markets. The localization strategy in the Thai market will be promoted to Indonesia and Vietnam. The company achieved rapid growth in the European market and established a scientific advisory committee in the field of respiratory therapy to enhance brand influence. Revenue in the North American market saw significant growth, with the strategic cooperation with Inogen continuing to deepen, and the South American market also resumed rapid growth in the third quarter

    Zhitong·
    SZ
    002223
    -0.14%
    Zhitong·
    SZ
    002223
    -0.14%

    YUYUE MEDICAL released its performance for the first three quarters, with a net profit attributable to the parent company of 1.466 billion yuan, a decrease of 4.28%

    According to the Zhitong Finance APP, YUYUE MEDICAL released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 6.545 billion yuan, a year-on-year increase of 8.58%. The net profit attributable to shareholders of the listed company was 1.466 billion yuan, a year-on-year decrease of 4.28%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.169 billion yuan, a year-on-year decrease of 8.21%. The basic earnings per share were 1.4687 yuan

    Zhitong·
    SZ
    002223
    -0.14%
    Zhitong·
    SZ
    002223
    -0.14%

    In the first three quarters of 2025, YUYUE MEDICAL achieved operating revenue of 6.545 billion yuan

    YUYUE MEDICAL released its third-quarter report for 2025, with the company achieving operating revenue of 6.545 billion yuan in the first three quarters, a year-on-year increase of 8.58%; net profit attributable to the parent company was 1.466 billion yuan; net operating cash flow was 1.504 billion yuan, a year-on-year increase of 8.77%; the company plans to implement its first third-quarter dividend since going public, distributing 2 yuan for every 10 shares, totaling a cash dividend of 200 million yuan

    Wallstreetcn·
    SZ
    002223
    -0.14%
    Wallstreetcn·
    SZ
    002223
    -0.14%

    Zhejiang Merchants Securities: Maintain YUYUE MEDICAL "Buy" rating, full-year revenue and profit growth is expected

    Zhejiang Merchants Securities maintains a "Buy" rating on YUYUE MEDICAL, expecting revenue and profit growth for the full year of 2025. In the first half of 2023, YUYUE MEDICAL's net profit attributable to the parent company was 1.203 billion yuan, a year-on-year increase of 7.4%. Among them, the net profit attributable to the parent company in Q2 was 578 million yuan, a year-on-year increase of 25%. Overseas revenue continues to grow, with H1 overseas revenue reaching 607 million yuan in 2025, a year-on-year increase of 26.6%. All product lines performed well, with high growth achieved in respiratory therapy, blood glucose, and emergency rescue sectors. The company is in a period of expanding overseas channels and promoting new products, and it is expected that the net profit margin will remain at a high level

    Zhitong·
    SZ
    002223
    -0.14%
    Zhitong·
    SZ
    002223
    -0.14%

    Ping An Securities: Maintains "Strong Buy" rating on YUYUE MEDICAL, optimistic about the company's sustained growth capability

    Ping An Securities maintains a "Strong Buy" rating on YUYUE MEDICAL, believing that the company has strong sustainable growth capabilities. In the first half of 2025, YUYUE MEDICAL achieved a net profit attributable to the parent company of 1.203 billion yuan, a year-on-year increase of 7.37%; in the second quarter, the net profit attributable to the parent company was 578 million yuan, a year-on-year increase of 25.43%. The company has performed outstandingly in businesses such as blood glucose AED, and its overseas operations are steadily advancing, becoming an important driver of performance growth. YUYUE MEDICAL is building a health management ecosystem of "hardware + software + data" and has launched the YUYUE AIAgent application to enhance user stickiness

    Zhitong·
    SZ
    002223
    -0.14%
    Zhitong·
    SZ
    002223
    -0.14%
    © 2025 Longbridge｜Disclaimer